Search | Clinical Trials Finder

Conditions: Hypertension
Interventions: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Stage 2 Systolic Hypertension
Interventions: valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension, Diabetes Mellitus, Type 2
Interventions: Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function; Drug · Device · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 35 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension
Interventions: Hydrochlorothiazide (HCTZ), Chlorthalidone (CTD); Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years and older
Enrollment: 20,723 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 69
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 64 more

Conditions: Chronic Kidney Disease
Interventions: Diuretic initiation or augmentation; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension, Metabolic Syndrome
Interventions: Aliskerin/Valsartan and Rampiril; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypertension, Hyperlipidemia
Interventions: Free Generic Samples (hydrochlorothiazide, simvastatin); Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 660 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension, Hyperlipidemia
Interventions: Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide); Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Hypertension
Interventions: Valsartan/Hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 648 participants
Timeline: Started 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension, Systolic, Stiffness, Aortic
Interventions: Clonidine, Hydrochlorothiazide, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 60 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Iowa City, Iowa

Conditions: Hypertension, Blood Pressure, High
Interventions: Ramipril and hydrochlorothiazide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 51 more

Conditions: Hypertension
Interventions: Olmesartan medoxomil, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 228
States / cities: Birmingham, Alabama • Columbiana, Alabama • Gulf Shores, Alabama + 225 more

Conditions: Hyperparathyroidism
Interventions: HCTZ cessation; Procedure
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Healthy
Interventions: Moexipril HCl/hydrochlorothiazide 15/25 mg tablets, UNIRETIC® 15/25 mg tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 2
States / cities: Saint Charles, Missouri • Houston, Texas

Conditions: Hypertension, High Blood Pressure
Interventions: Losartan, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 65 Years and older
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension in Pregnancy, Postpartum Preeclampsia
Interventions: ACE Inhibitors and Diuretics, NIFEdipine ER; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension
Interventions: Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress; Drug · Dietary Supplement · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension
Interventions: Valsartan + HCTZ, Valsartan, HCTZ; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 70 Years and older
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Escondido, California + 17 more

Conditions: Hypertension
Interventions: HCTZ + Amlodipine, Valsartan/HCTZ; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Muscle Shoals, Alabama • Westlake Village, California • Oklahoma City, Oklahoma + 2 more

Conditions: Hypertension
Interventions: Nebivolol, Hydrochlorothiazide; Drug
Lead sponsor: InVasc Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tucker, Georgia

Conditions: Hypertension
Interventions: amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 72
States / cities: Birmingham, Alabama • Green Valley, Arizona • Mesa, Arizona + 69 more

Conditions: Type 2 Diabetes Mellitus, Vascular Disease
Interventions: Spironolactone, Hydrochlorothiazide + potassium, Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Hydrochlorothiazide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 16
States / cities: Fort Lauderdale, California • Long Beach, California • Roseville, California + 13 more

Search by objective public record fields.

Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

Diuretic Comparison Project

Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

The Effect of Providing Free Samples of Generic Cardiovascular Medications to Physicians

The SCCS Polypill Pilot Trial

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

Sympathetic Regulation of Large Artery Stiffness in Humans With ISH

Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension

Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism

Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions

N-of-1 Trials for Blood Pressure Medications in Adults

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension

Treatment of Supine Hypertension in Autonomic Failure

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension